371 related articles for article (PubMed ID: 32449439)
21. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
22. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
Fisher AC; Kamga MH; Agarabi C; Brorson K; Lee SL; Yoon S
Trends Biotechnol; 2019 Mar; 37(3):253-267. PubMed ID: 30241924
[TBL] [Abstract][Full Text] [Related]
23. Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales.
Hummel J; Pagkaliwangan M; Gjoka X; Davidovits T; Stock R; Ransohoff T; Gantier R; Schofield M
Biotechnol J; 2019 Feb; 14(2):e1700665. PubMed ID: 29341493
[TBL] [Abstract][Full Text] [Related]
24. Accelerating Process Development and Product Formulation.
Futran M; Muzzio F; Chatterjee B
Pharm Res; 2024 May; 41(5):833-837. PubMed ID: 38698195
[TBL] [Abstract][Full Text] [Related]
25. Does R&D pay?
Cavalla D; Minhas R
Drug Discov Today; 2010 Mar; 15(5-6):230-4. PubMed ID: 19931643
[TBL] [Abstract][Full Text] [Related]
26. [Developability assessment].
Dumas J; Huille S; Prades C
Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
[TBL] [Abstract][Full Text] [Related]
27. Lifecycle management for recombinant protein production using mammalian cell culture technology.
Moran E; Gammell P
Adv Biochem Eng Biotechnol; 2014; 139():245-56. PubMed ID: 24196316
[TBL] [Abstract][Full Text] [Related]
28. Sources of innovation for new medicines: questions of sustainability.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2021 Jan; 26(1):240-247. PubMed ID: 33144150
[TBL] [Abstract][Full Text] [Related]
29. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
30. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
[TBL] [Abstract][Full Text] [Related]
31. Japan unveils 5-year plan to boost clinical research.
McCurry J
Lancet; 2007 Apr; 369(9570):1333-6. PubMed ID: 17455378
[No Abstract] [Full Text] [Related]
32. Patient-centric Comparability Assessment of Biopharmaceuticals.
Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
[TBL] [Abstract][Full Text] [Related]
33. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
34. [Drug development costs are overstated by the industry].
Jeppsson A
Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
[No Abstract] [Full Text] [Related]
35. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
Reichert JM; Beck A; Iyer H
MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
[TBL] [Abstract][Full Text] [Related]
36. Public-sector Contributions to Novel Biologic Drugs.
Nayak RK; Lee CC; Avorn J; Kesselheim AS
JAMA Intern Med; 2021 Nov; 181(11):1522-1525. PubMed ID: 34279545
[TBL] [Abstract][Full Text] [Related]
37. At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products.
Varmaghani M; Heidari E; Reiner Ž; Sahebkar A
J Med Econ; 2020 Oct; 23(10):1193-1195. PubMed ID: 32580595
[No Abstract] [Full Text] [Related]
38. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
39. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.
Jackson N; Atar D; Borentain M; Breithardt G; van Eickels M; Endres M; Fraass U; Friede T; Hannachi H; Janmohamed S; Kreuzer J; Landray M; Lautsch D; Le Floch C; Mol P; Naci H; Samani NJ; Svensson A; Thorstensen C; Tijssen J; Vandzhura V; Zalewski A; Kirchhof P
Eur Heart J; 2016 Mar; 37(9):747-54. PubMed ID: 26077039
[TBL] [Abstract][Full Text] [Related]
40. End-to-end collaboration to transform biopharmaceutical development and manufacturing.
Erickson J; Baker J; Barrett S; Brady C; Brower M; Carbonell R; Charlebois T; Coffman J; Connell-Crowley L; Coolbaugh M; Fallon E; Garr E; Gillespie C; Hart R; Haug A; Nyberg G; Phillips M; Pollard D; Qadan M; Ramos I; Rogers K; Schaefer G; Walther J; Lee K
Biotechnol Bioeng; 2021 Sep; 118(9):3302-3312. PubMed ID: 33480041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
